Genprex Annual Meeting Decisions: Director, Audits, and Compensation
Company Announcements

Genprex Annual Meeting Decisions: Director, Audits, and Compensation

Genprex (GNPX) just unveiled an announcement.

At Genprex’s 2024 Annual Meeting, stockholders re-elected Brent M. Longnecker as a Class I director, ratified the appointment of WithumSmith+Brown, PC as the independent accounting firm, and approved the executive compensation plan. Furthermore, it was decided that votes on executive compensation will be held annually, with the next advisory vote scheduled no later than the 2030 Annual Meeting. Additionally, the Board implemented a revised compensation policy for non-executive Board Chairs, introducing an annual cash retainer of $15,000.

For a thorough assessment of GNPX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyGenprex forms Mesothelioma Clinical Advisory Board
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyGenprex plans to launch separate company to focus on gene therapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App